In addition to a change to an M1 phenotype of the CCR2+ MDSCs in mice treated with the CCR2 antagonist, we were surprised to find considerable CCR2 expression by the tumor cells themselves (Figure 1). The gene discussed is CCR2; the disease is neoplasm.